$0.08
2.56%
Nasdaq, Dec 26, 03:30 pm CET
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Altamira Therapeutics Ltd Stock price

$0.08
-0.32 80.13% 1M
-1.03 92.79% 6M
-3.40 97.70% YTD
-2.70 97.12% 1Y
-547.92 99.99% 3Y
-591.92 99.99% 5Y
-31,359.92 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Key metrics

Market capitalization $300.00k
Enterprise Value $660.00k
P/E (TTM) P/E ratio 0.00
P/B ratio (TTM) P/B ratio 0.03
Short interest 1.35%

Is Altamira Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Altamira Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

Buy
100%

Financial data from Altamira Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
8% 8%
-
-0.13 -0.13
8% 8%
-
- Selling and Administrative Expenses 3.22 3.22
133% 133%
-
- Research and Development Expense 3.38 3.38
78% 78%
-
-6.73 -6.73
17% 17%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -6.87 -6.87
17% 17%
-
Net Profit -4.31 -4.31
84% 84%
-

In millions USD.

Don't miss a Thing! We will send you all news about Altamira Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altamira Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
9 days ago
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common shares from...
Neutral
GlobeNewsWire
3 months ago
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a m...
Neutral
GlobeNewsWire
3 months ago
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whol...
More Altamira Therapeutics Ltd News

Company Profile

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Thomas Meyer
Employees 12
Founded 2003
Website www.altamiratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today